Global Osteosarcoma Drug Market – Industry Trends and Forecast to 2030

Global Osteosarcoma Drug Market, By Types (Central Tumor and Surface Tumor), Treatment (Surgery and Medication), Mechanism of Action (TopoIsomerase Inhibitor, RNA Synthesis Inhibitor, Dihydrofolic Acid Reductase Inhibitor, Monoclonal Antibodies, and Others), Drugs (Doxorubicin, Methotrexate, Dactinomycin, Denosumab, Cyclophosphamide and Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Osteosarcoma Drug Market Analysis and Size

The market growth is anticipated to increase due to the rise in metabolic disorders and chronic kidney disease (CKD). Most people over the age of 50 are expected to suffer from osteoporosis, while some may be at risk of developing the bone disease. Osteosarcoma is the most common type of cancer and usually occurs in children and young adults. The rapid increase in the need for new treatments for rare cancers such as osteosarcoma offers potential opportunities for market growth in the coming years.                                

Data Bridge Market Research analyses that the osteosarcoma drug market which was USD 1,200.00 million in 2022, would rocket up to USD 1,840.00 million by 2030, and is expected to undergo a CAGR of 5.50% during the forecast period. This indicates that the market value. “Oral” dominates the route of administration segment of the osteosarcoma drug market owing to the growing demand for oral medication for the treatment of osteosarcoma. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Osteosarcoma Drug Market Scope and Segmentation

Market Definition

The global osteosarcoma drug market specifically refers to business activities and transactions related to drugs and therapies developed and marketed for the treatment of osteosarcoma. Osteosarcoma is a rare form of bone cancer that mainly affects children and young adults. The market includes the research, development, production, marketing and sale of drugs and therapies for the diagnosis, treatment and cure of osteosarcoma.            

Osteosarcoma Drug Market Dynamics

Drivers

• Increasing drug approvals by several market players

More and more drug approvals are driving the growth of the market. For instance, in 2010 the FDA approved a monoclonal antibody called Denosumab to treat postmenopausal women at high risk of fractures. In addition, teriparatide is a synthetic form of parathyroid hormone and is the only FDA-approved anabolic drug. Phosphate binders and dialysis are also widely used in the treatment of hyperphosphatemia. This will boost the growth of the market.

• Research and development proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the therapeutic drugs will further create lucrative market growth opportunities. Research and development proficiencies being conducted to develop the osteosarcoma treatment is also bolstering the market growth rate.

• Growing investment for healthcare facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Increased demand for chemotherapy

Increasing demand for chemotherapy is driving the growth of the market. For instance, Merck KGaA, a biopharmaceutical company in Darmstadt, Germany, in the United States and EMD Serono and Pfizer Inc. in Canada announced that the US Food and Drug Administration has approved the Supplemental Biologics License Application (sBLA) for BAVENCIO (avelumab). ) in April 2020 for the treatment of locally advanced or metastatic urothelial carcinoma (UC). Therefore, this factor contributes to the growth of the market.

• Increasing strategic alliances among market players

Major market players are focusing on inorganic growth strategies that are expected to drive market growth during the forecast period of 2023-2030. For instance, Amgen, one of the leading biotechnology companies in the world, is primarily focused on the clinical development and commercialization of MP0310, entering into a strategic collaboration with Molecular Partners in December 2018. MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP in tumor stromal cells and stimulating T cells with 4-1BB. Therefore, this factor accelerates the growth of the market.

Restraints/ Challenges

• Risk of side-effects

Many side effects associated with osteosarcoma drug may limit the growth of the global osteosarcoma drug market during the forecast period. Side effects such as dyspepsia, headache and to some extent myalgia, flushing, lower back pain and rhinitis have been reported with osteosarcoma medication. Therefore, these effects hinder the growth of the market.

• Lack of knowledge and awareness about osteosarcoma

Lack of expertise and knowledge about bone cancer in some low- and middle-income countries, such as Kenya and India, hinders market growth. Osteosarcoma is also not widely reported in these countries. Therefore, the availability of treatment is also lower. Therefore, this factor hinders the growth of the market.

This osteosarcoma drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteosarcoma drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In December 2021, the Centers for Devices and Radiological Health of the FDA granted ZetaMet's breakthrough device for the treatment of metastatic bone cancers and osteological interventions.
•  In October 2020, Johnson and Johnson completed the acquisition of Momenta Pharmaceuticals Inc. acquisition to provide additional potential in various diseases, including infectious diseases and vaccines, neuroscience, oncology and pulmonary hypertension.

Global Osteosarcoma Drug Market Scope

The osteosarcoma drug market is segmented on the basis of types, treatment, mechanism of action, drugs, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Central Tumor
• Surface Tumor

Treatment

• Surgery
• Medication

Mechanism of Action

• Topo Isomerase Inhibitor
• RNA Synthesis Inhibitor
• Dihydrofolic Acid Reductase Inhibitor
• Monoclonal Antibody
• Others

Drugs

• Doxorubicin
• Methotrexate
• Dactinomycin
• Denosumab
• Cyclophosphamide
• Others

Route of Administration

• Oral
• Parenteral

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Osteosarcoma Drug Market Regional Analysis/Insights

The osteosarcoma drug market is analysed and market size insights and trends are provided by country types, treatment, mechanism of action, drugs, route of administration, end users and distribution channel as referenced above.

The countries covered in the osteosarcoma drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market because the presence of major key manufacturers of the product is high and growing research and development activities. The rise in the occurrence of bone cancer will boost the growth of the osteosarcoma drug market in the region during the forecast period 2023-2030.   

Asia-Pacific has been witnessing positive growth for osteosarcoma drug market throughout the forecasted period because of the increased new research and developments on osteosarcoma drug. Also, the incidence of well settled healthcare infrastructure is also increasing the market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The osteosarcoma drug market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for osteosarcoma drug market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the osteosarcoma drug market. The data is available for historic period 2021-2030.

Competitive Landscape and Osteosarcoma Drug Market Share Analysis

The osteosarcoma drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteosarcoma drug market.

Some of the major players operating in the osteosarcoma drug market are:

• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland.)
• Hikma Pharmaceuticals plc (U.K.)
• Aurobindo Pharma (India)
• Melinta Therapeutics, Inc (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• Lilly (U.S.)
• Amgen Inc. (U.S.)
• Bellicum Phamaceuticals, Inc (U.S.)
• Incyte (U.S.)
• Nektar Therapeutics (U.S.)
•  Iovance Biotherapeutics (U.S.)
• Aurora biopharma (U.S.)
• BioAtla (U.S.)
• Acrotech Biopharma, Inc. (U.S.)
• Eleison Pharmaceuticals (U.S.)